Current and future therapies for age-related macular degeneration

Expert Opinion on Emerging Drugs

Volumn 14, Issue 2, 2009, Pages 341-362

  Beutel, Julia ^a   Rudolf, Martin ^a   Grisanti, Salvatore ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

Age related macular degeneration; Angiogenesis; Apoptosis; Inflammation; Therapy; VEGF

Indexed keywords

ACZ 885; AFLIBERCEPT; AGN 211745; ALPHA TOCOPHEROL; ANECORTAVE; ANTIOXIDANT; ARC 1905; ATG 003; BATIMASTAT; BEVACIZUMAB; BEVASIRANIB; BROMFENAC; CGC 11047; COMBRETASTATIN A4 PHOSPHATE; DEXAMETHASONE; E 10030; ICO 007; JPE 1375; JSM 6427; JSM 7717; KH 902; LT 1009; MATRIX METALLOPROTEINASE INHIBITOR; MD 710820; MONOCLONAL ANTIBODY LM 609; NT 501; OMEGA 3 FATTY ACID; ORA 102; ORA102; OT 551; PAZOPANIB; PEGAPTANIB; PF 04523655; PHOSPHOTRANSFERASE INHIBITOR; PRINOMASTAT; RANIBIZUMAB; RAPAMYCIN; RECOMBINANT PROTEIN; SEMAXANIB; SQUALAMINE; ST 602; SUNITINIB; TG 100801; TRIAMCINOLONE; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VATALANIB; VERTEPORFIN; XANTHOPHYLL; ZEAXANTHIN;

ANGIOGENESIS; APOPTOSIS; BLEEDING; CLINICAL TRIAL; COLORECTAL CANCER; DRUG COST; DRUG EFFICACY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG WITHDRAWAL; ENDOPHTHALMITIS; HEART INFARCTION; HUMAN; HYPERTENSIVE CRISIS; NEPHROTIC SYNDROME; NEUROPROTECTION; NONHUMAN; PHOTODYNAMIC THERAPY; PROTEIN EXPRESSION; RETINA MACULA AGE RELATED DEGENERATION; RETINA MACULA DEGENERATION; REVIEW; SIGNAL TRANSDUCTION; SINGLE DRUG DOSE; STROKE; SUBRETINAL NEOVASCULARIZATION; THROMBOEMBOLISM; UNSPECIFIED SIDE EFFECT; UVEITIS; VISION; VISUAL IMPAIRMENT;

ANGIOGENESIS INHIBITORS; CLINICAL TRIALS AS TOPIC; DRUG THERAPY, COMBINATION; DRUGS, INVESTIGATIONAL; HUMANS; MACULAR DEGENERATION; PHOTOCHEMOTHERAPY; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 67649373135     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728210902824141     Document Type: Review

References (94)

1. Evans J, Wormald R. Is the incidence of registrable age related macular degeneration increasing? Br J Ophthalmol 1996;80:9-14
2. van Leeuwen R, Klaver CC, Vingerling JR, et al. Epidemiology of age-related maculopathy: a review. Eur J Epidemiol 2003;18:845-854 (Pubitemid 37169020)
3. Age-Related Eye Disease Study Research Group. A randomized, placebo-controlled, clinical trial of high-dose supplementation with vitamins C and E, beta carotene, and zinc for age-related macular degeneration and vision loss: AREDS report no. 8. Arch Ophthalmol 2001;119:1417-1436 (Pubitemid 32963246)
4. Davis MD, Gangnon RE, Lee LY, et al. The Age-Related Eye Disease Study severity scale for age-related macular degeneration: AREDS Report No. 17. Arch Ophthalmol 2005;123:1484-1498 (Pubitemid 41626684)
5. Klein R, Klein BE, Tomany SC, et al. Ten-year incidence and progression of age-related maculopathy: the Beaver Dam eye study. Ophthalmology 2002;109:1767-1779
6. Wang JJ, Rochtchina E, Lee AJ, et al. Ten-year incidence and progression of age-related maculopathy: the Blue Mountains Eye Study. Ophthalmology 2007;114:92-98 (Pubitemid 46014292)
7. Complications of Age-Related Macular Degeneration Prevention Trial Research Group (CAPT Research Group). Laser treatment in patients with bilateral large drusen: the complications of age-related macular degeneration prevention trial. Ophthalmology 2006;1974-1986
8. Bressler NM. Early detection and treatment of neovascular age-related macular degeneration. J Am Board Fam Pract 2002;15:142-152 (Pubitemid 34415866)
9. Treatment of Age-Related Macular Degeneration With Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization image-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials. Arch Ophthalmol 1999;117:1329-1345
10. Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials. Arch Ophthalmol 2001;119:198-207 (Pubitemid 32147926)
11. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization. Am J Ophthalmol 2001;131:541-560 (Pubitemid 32427660)
12. Blinder KJ, Bradley S, Bressler NM, et al. Effect of lesion size, visual acuity, and lesion composition on visual acuity change with and without verteporfin therapy for choroidal neovascularization secondary to age-related macular degeneration. Am J Ophthalmol 2003;136:407-418 (Pubitemid 37101236)
13. Azab M, Benchaboune M, Blinder KJ, et al. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: meta-analysis of 2-year safety results in three randomized clinical trials. Retina 2004;24:1-12
14. Arnold JJ, Blinder KJ, Bressler NM, et al. Acute severe visual acuity decrease after photodynamic therapy with verteporfin: case reports from randomized clinical trials. Am J Ophthalmol 2004;137:683-696 (Pubitemid 38446683)
15. Ruckman J, Green LS, Beeson J, et al. 2′-Fluoropyrimidine RNA-based aptamers to the 165-amino acid form of vascular endothelial growth factor (VEGF165): inhibition of receptor binding and VEGF-induced vascular permeability through interactions requiring the exon 7-encoded domain. J Biol Chem 1998;273:20556-20567 (Pubitemid 28377626)
16. Chakravarthy U, Adamis AP, Cunningham ET, et al. Year 2 efficacy results of 2 randomized controlled clinical trials of pegaptanib for neovascular age-related macular degeneration. Ophthalmology 2006;113:1508-1521
17. D'Amico DJ, Masonson HN, Patel M, et al. Pegaptanib sodium for neovascular age-related macular degeneration: two-year safety results of the two prospective, multicenter, controlled clinical trials. Ophthalmology 2006;113:992-1001 (Pubitemid 43795228)
18. Gragoudas ES, Adamis AP, Cunningham ET Jr, et al. Pegaptanib for neovascular age-related macular degeneration. N Engl J Med 2004;351:2805-2816 (Pubitemid 40051904)
19. Kaiser PK. Antivascular endothelial growth factor agents and their development: therapeutic implications in ocular diseases. Am J Ophthalmol 2006;142:660-668 (Pubitemid 44442083)
20. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992;7:53-64
21. Chen Y, Wiesmann C, Fuh G, et al. Selection and analysis of an optimized anti-VEGF antibody: crystal structure of an affinity-matured Fab in complex with antigen. J Mol Biol 1999;293:865-881 (Pubitemid 29527672)
22. Rosenfeld PJ, Schwartz SD, Blumenkranz MS, et al. Maximum tolerated dose of a humanized anti-vascular endothelial growth factor antibody fragment for treating neovascular age-related macular degeneration. Ophthalmology 2005;112:1048-1053 (Pubitemid 40797460)
23. Bakri SJ, Snyder MR, Reid JM, et al. Pharmacokinetics of intravitreal bevacizumab (Avastin). Ophthalmology 2007;114:855-859 (Pubitemid 46635858)
24. Martínez-Castellanos MA, Quiroz-Mercado H, et al. Twelve-month safety of intravitreal injections of bevacizumab (Avastin(R)): results of the Pan-American Collaborative Retina Study Group (PACORES). Graefes Arch Clin Exp Ophthalmol 2008;246:81-87
25. Antoszyk AN, Tuomi L, Chung CY, Singh A; FOCUS Study Group. Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration (FOCUS): year 2 results. Am J Ophthalmol. 2008;145:862-874
26. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007;27:133-140 (Pubitemid 46245638)
27. Azab M, Boyer DS, Bressler NM, et al. Verteporfin therapy of subfoveal minimally classic choroidal neovascularization in age-related macular degeneration: 2-year results of a randomized clinical trial. Arch Ophthalmol 2005;123:448-457 (Pubitemid 40489914)
28. Meads C, Salas C, Roberts T, et al. Clinical effectiveness and cost-utility of photodynamic therapy for wet age-related macular degeneration: a systemic review and economic evaluation. Health Technol Assess 2003;7:1-98 (Pubitemid 37321488)
29. Owen CG, Flethcher AE, Donoghue M, et al. How big is the burden of visual loss caused by age related macular degeneration in the United Kingdom? Br J Ophthalmol 2003;87:312-317
30. Age-Related Eye Disease Study Research Group. Potential public health impact of Age-Related Eye Disease Study results: AREDS report no. 11. Arch Ophthalmol 2003;121:1621-1624 (Pubitemid 37392370)
31. Friedman DS, O'Colmain BJ, Muñoz B, et al. Eye Diseases Prevalence Research Group. Prevalence of age-related macular degeneration in the United States. Arch Ophthalmol 2004;122:564-572
32. Xu L, Wang Y, Li Y, et al. Causes of blindness and visual impairment in urban and rural areas in Beijing: the Beijing Eye Study. Ophthalmology 2006;113:1134 (Pubitemid 43947225)
33. Ciardella AP, Donsoff IM, Guyer DR, et al. Antiangiogenesis agents. Ophthalmol Clin North Am 2002;15:453-458 (Pubitemid 36076600)
34. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000;407:249-257
35. Zhang M, Yu D, Yang C, et al. The pharmacology study of a new recombinant human VEGF receptor-Fc fusion protein on experimental choroidal neovascularization [abstract]. Pharm Res 2009;26:204-210
36. Kleinman ME, Yamada K, Takeda A, et al. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3. Nature 2008;452:591-597
37. Kyowa Hakko Kogyo KK. Anti-human VEGF receptor Flt-1 monoclonal antibody. US6617160; 2003
38. Leonard P, Scotney PD, Jabeen T, et al. Crystal structure of vascular endothelial growth factor-B in complex with a neutralising antibody Fab fragment. J Mol Biol. 2008;384:1203-1217
39. Ozaki H, Seo MS, Ozaki K, et al. Blockade of vascular endothelial cell growth factor receptor signaling is sufficient to completely prevent retinal neovascularization. Am J Pathol 2000;156:697-707 (Pubitemid 30643824)
40. Doukas J, Mahesh S, Umeda N, et al. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema. J Cell Physiol 2008;216:29-37 (Pubitemid 351813092)
41. Saishin Y, Silva RL, Saishin Y, et al. Periocular injection of microspheres containing PKC412 inhibits choroidal neovascularization in a porcine model. Invest Ophthalmol Vis Sci 2003;44:4989-4993 (Pubitemid 37315317)
42. Clark EA, Brugge JS. Integrins and signal transduction pathways: the road taken. Science 1995;268:233-239
43. Takahashi T, Ueno H, Shibuya M. VEGF activates protein kinase C-dependent, but Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial cells. Oncogene 1999;18:2221-2230 (Pubitemid 29186923)
44. Danis R, Criswell M, Orge F, et al. Intravitreous anti-raf-1 kinase antisense oligonucleotide as an angioinhibitory agent in porcine preretinal neovascularization. Curr Eye Res 2003;26:45-54 (Pubitemid 37467870)
45. Donsante A, Miller DG, Li Y, et al. AAV vector integration sites in mouse hepatocellular carcinoma. Science 2007;317:477 (Pubitemid 47196106)
46. Donsante A, Vogler C, Muzyczka N, et al. Observed incidence of tumorigenesis in long-term rodent studies of rAAV vectors. Gene Ther 2001;8:1343-1346 (Pubitemid 32834303)
47. Pechan P, Rubin H, Lukason M, et al. Novel anti-VEGF chimeric molecules delivered by AAV vectors for inhibition of retinal neovascularization. Gene Ther 2009;16:10-16
48. Grimm C, Wenzel A, Groszer M, et al. HIF-1-induced erythropoietin in the hypoxic retina protects against light-induced retinal degeneration. Nat Med 2002;8:718-724 (Pubitemid 34778725)
49. Jaquet K, Krause K, Tawakol-Khodai M, et al. Erythropoietin and VEGF exhibit equal angiogenic potential. Microvasc Res 2002;64:326-333
50. Watanabe D, Suzuma K, Matsui S, et al. Erythropoietin as a retinal angiogenic factor in proliferative diabetic retinopathy. N Engl J Med 2005;353:782-792 (Pubitemid 41215487)
51. Campochiaro PA, Hackett SF. Ocular neovascularization: a valuable model system. Oncogene 2003;22:6537-6548 (Pubitemid 37372333)
52. Joussen AM, Poulaki V, Tsujikawa A, et al. Suppression of diabetic retinopathy with angiopoietin-1. Am J Pathol 2002;160:1683-1693 (Pubitemid 34525648)
53. Tait CR, Jones PF. Angiopoietins in tumours: the angiogenic switch. J Pathol 2004;204:1-10 (Pubitemid 39214476)
54. Ozaki H, Yu AY, Della N, et al. Hypoxia inducible factor-1alpha is increased in ischemic retina: temporal and spatial correlation with VEGF expression. Invest Ophthalmol Vis Sci 1999;40:182-189 (Pubitemid 29029587)
55. Forsythe JA, Jiang BH, Iyer NV, et al. Activation of vascular endothelial growth factor gene transcriptionby hypoxia-inducible factor 1. Mol Cell Biol 1996;16:4604-4613 (Pubitemid 26272112)
56. Wang B, Li H, Yan H, et al. Genistein inhibited hypoxia- inducible factor-1alpha expression induced by hypoxia and cobalt chloride in human retinal pigment epithelium cells. Methods Find Exp Clin Pharmacol 2005;27:179-184 (Pubitemid 40571212)
57. Hynes RO. A reevaluation of integrins as regulators of angiogenesis. Nat Med 2002;8:918-921 (Pubitemid 35033683)
58. Brooks PC, Clark RA, Cheresh DA. Requirement of vascular integrin alpha v beta 3 for angiogenesis. Science 1994;264:569-571 (Pubitemid 24185862)
59. Friedlander M, Theesfeld CL, Sugita M, et al. Involvement of integrins alpha v beta 3 and alpha v beta 5 in ocular neovascular diseases. Proc Natl Acad Sci USA 1996;93:9764-9769
60. Mikecz K. Vitaxin applied molecular evolution. Curr Opin Investig Drugs 2000;1:199-203 (Pubitemid 30811020)
61. Morgunova E, Tuuttila A, Bergmann U, et al. Structure of human pro-matrix metalloproteinase-2: activation mechanism revealed. Science 1999;284:1667-1670 (Pubitemid 29291376)
62. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980;284:67-68 (Pubitemid 10098769)
63. Steen B, Sejersen S, Berglin L, et al. Matrix metalloproteinases and metalloproteinase inhibitors in choroidal neovascular membranes. Invest Ophthalmol Vis Sci 1998;39:2194-2200 (Pubitemid 28455093)
64. Lambert V, Munaut C, Jost M, et al. Matrix metalloproteinase-9 contributes to choroidal neovascularization. Am J Pathol 2002;161:1247-1253
65. Griffioen AW. AG-3340 (Agouron Pharmaceuticals Inc). IDrugs 2000;3:336-345
66. Takahashi T, Nakamura T, Hayashi A, et al. Inhibition of experimental choroidal neovascularization by overexpression of tissue inhibitor of metalloproteinases-3 in retinal pigment epithelium cells. Am J Ophthalmol 2000;130:774-781 (Pubitemid 32000859)
67. Das A, McLamore A, Song W, et al. Retinal neovascularization is suppressed with a matrix metalloproteinase inhibitor. Arch Ophthalmol 1999;117:498-503 (Pubitemid 29169645)
68. Cheng L, Rivero ME, Garcia CR, et al. Evaluation of intraocular pharmacokinetics and toxicity of prinomastat (AG3340) in the rabbit. J Ocul Pharmacol Ther 2001;17:295-304 (Pubitemid 32656550)
69. Griffioen AW. AG-3340 (Agouron Pharmaceuticals Inc). IDrugs 2000;3:336-345
70. Ando A, Yang A, Nambu H, et al. Blockade of nitric-oxide synthase reduces choroidal neovascularization. Mol Pharmacol 2002;62:539-544 (Pubitemid 36329372)
71. Ando A, Yang A, Mori K, et al. Nitric oxide is proangiogenic in the retina and choroid. J Cell Physiol 2002;191:116-124 (Pubitemid 34195223)
72. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994;79:315-328 (Pubitemid 24324921)
73. Tonini T, Rossi F, Claudio PP. Molecular basis of angiogenesis and cancer. Oncogene 2003;22:6549-6556 (Pubitemid 37372334)
74. Sima J, Zhang SX, Shao C, et al. The effect of angiostatin on vascular leakage and VEGF expression in rat retina. FEBS Lett 2004;564:19-23 (Pubitemid 38490695)
75. Lai CC, Wu WC, Chen SL, et al. Suppression of choroidal neovascularization by adeno-associated virus vector expressing angiostatin. Invest Ophthalmol Vis Sci 2001;42:2401-2407 (Pubitemid 32848872)
76. Raisler BJ, Berns KI, Grant MB, et al. Adeno-associated virus type-2 expression of pigmented pithelium-derived factor or kringles 1-3 of angiostatin reduce retinal neovascularization. Proc Natl Acad Sci USA 2002;99:8909-8914 (Pubitemid 34693657)
77. O'reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997;88:277-285
78. Marneros AG, Olsen BR. Physiological role of collagen XVIII and endostatin. FASEB J 2005;19:716-728 (Pubitemid 40617376)
79. Mori K, Ando A, Gehlbach P, et al. Inhibition of choroidal neovascularization by intravenous injection of adenoviral vectors expressing secretable endostatin. Am J Pathol 2001;159:313-320 (Pubitemid 33704216)
80. Dawson DW, Volpert OV, Gillis P, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999;285:245-248 (Pubitemid 29329995)
81. Mori K, Duh E, Gehlbach P, et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001;188:253-263 (Pubitemid 32622916)
82. Mori K, Gehlbach P, Ando A, et al. Regression of ocular neovascularization in response to increased expression of pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2002;43:2428-2434 (Pubitemid 34700678)
83. Rasmussen H, Chu KW, Campochiaro P, et al. Clinical protocol: an open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001;12:2029-2032
84. Campochiaro PA, Nguyen QD, Shah SM, et al. Adenoviral vector-delivered pigment epithelium-derived factor for neovascular age-related macular degeneration: results of a phase I clinical trial. Hum Gene Ther 2006;17:167-176 (Pubitemid 43262032)
85. Stahl A, Paschek L, Martin G, et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett 2008;582:3097-3102
86. D'Amico DJ, Goldberg MF, Hudson H, et al. Anecortave acetate as monotherapy for the treatment of subfoveal lesions in patients with exsudative age-related macular degeneration (AMD): interim (month 6) analysis of clinical safety and efficacy. Retina 2003;23:14-23 (Pubitemid 36348478)
87. Available form: www.clinicaltrials.gov ID NCT00333216
88. Sparrow JR, Boulton M. RPE lipofuscin and its role in retinal pathobiology. Exp Eye Res 2005;80:595-606 (Pubitemid 40602960)
89. Radu RA, Mata NL, Nusinowitz S, et al. Treatment with isotretinoin inhibits lipofuscin accumulation in a mouse model of recessive Stargardt's macular degeneration. Proc Natl Acad Sci USA 2003;100:4742-4747 (Pubitemid 36457800)
90. Hageman GS, Anderson DH, Johnson LV, et al. A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. Proc Natl Acad Sci USA 102:20:7227-7232 (Pubitemid 40696361)
91. Mousa E, Dier T, Kannanayakal G. Patil. Anti-angiogenesis efficacy of the novel NF-kB and oxidative stress inhibitor, OT-551. Invest Ophthalmol Vis Sci 2008;49:E-Abstract 4590
92. Piermarocchi S, Sartore M, Lo Giudice G, et al. Combination of photodynamic therapy and intraocular triamcinolone for exsudative age-related macular degeneration and long-term chorioretinal macular atrophy. Arch Ophthalmol 2008;126:1367-1374
93. Swaroop A, Branham KE, Chen W, Abecasis G. Genetic susceptibility to age-related macular degeneration: a paradigm for dissecting complex disease traits. Hum Mol Genet 2005;16:R174-82
94. Klein ML, Francis PJ, Rosner B, et al. CFH and LOC387715/ARMS2 genotypes and treatment with antioxidants and zinc for age-related macular degeneration. Ophthalmology 2008;115:1019-1025